Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2011 | 09-2011 | 06-2011 | 03-2011 | 12-2010 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,706 | 10,810 | 14,390 | 12,400 | 8,080 |
| Other current assets | 0 | 40 | 90 | 40 | 0 |
| TOTAL | $7,706 | $10,850 | $14,480 | $12,440 | $8,080 |
| Non-Current Assets | |||||
| PPE Net | 20 | 430 | 430 | 430 | 21 |
| Intangibles | 5,597 | 0 | 0 | 0 | 6,268 |
| Other Non-Current Assets | 27 | 5,780 | 5,950 | 6,120 | -10 |
| TOTAL | $5,644 | $6,210 | $6,380 | $6,550 | $6,280 |
| Total Assets | $13,350 | $16,660 | $20,460 | $18,590 | $14,400 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 101 | 140 | 370 | 240 | 410 |
| Accrued Expenses | 71 | 340 | 280 | 440 | 930 |
| Other current liabilities | N/A | 0 | 0 | 30 | 0 |
| TOTAL | $263 | $490 | $650 | $710 | $1,340 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 3,068 | 4,010 | 5,040 | 6,150 | 2,350 |
| TOTAL | $3,068 | $4,010 | $5,040 | $6,150 | $2,350 |
| Total Liabilities | $3,330 | $4,500 | $5,690 | $6,870 | $3,700 |
| Shareholders' Equity | |||||
| Common Shares | 111 | 110 | 100 | 100 | 90 |
| Retained earnings | -105,785 | -102,330 | -95,890 | -91,350 | -86,350 |
| Other shareholders' equity | 0 | 0 | 10 | 3,730 | 4,115 |
| TOTAL | $10,020 | $12,160 | $14,770 | $11,710 | $10,690 |
| Total Liabilities And Equity | $13,350 | $16,660 | $20,460 | $18,580 | $14,390 |